Home/ Stocks/ LXEO

Lexeo Therapeutics, Inc. Common Stock

LXEO XNAS

$5.83 +0.01 (+0.17%) ▲ 15-min delayed

Open

$5.82

High

$5.96

Low

$5.67

Volume

994.0K

Market Cap

$457.78M

About Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 59 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-99,961,000	$-1.86
FY 2025	$0	$-99,961,000	$-1.86
Q3 2025	$0	$-20,283,000	$-0.33
Q2 2025	$0	$-26,103,000	$-0.60

Related Market News

No specific coverage for LXEO yet. Check out our latest market news or earnings calendar.

Get LXEO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Lexeo Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.